Longer time to recovery from acute kidney injury is associated with major adverse kidney events in patients with cirrhosis.

Authors:
Patidar KR; Naved MA; Kabir S; Grama A; Allegretti AS and 7 more

Journal:
Aliment Pharmacol Ther

Publication Year: 2023

DOI:
10.1111/apt.17457

PMCID:
PMC10441172

PMID:
36883210

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Aliment Pharmacol Ther

Abbreviation: Aliment Pharmacol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic…
Wijarnpreecha K; Li F; Lundin SK and 5 more (2023) - Transparency Score: 3/6
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for s…
Hermann RP; Rockey DC; Suzuki A and 2 more (2022) - Transparency Score: 3/6
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disea…
Meade S; Patel KV; Luber RP and 17 more (2022) - Transparency Score: 4/6
Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogas…
Visaggi P; Ghisa M; Del Corso G and 11 more (2022) - Transparency Score: 3/6
Children included in randomised controlled trials of biologics in inflammatory bowel diseases do no…
Atia O; Pujol-Muncunill G; Navas-López VM and 10 more (2022) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT: ASA has received consulting fees from Mallinckrodt Pharmaceuticals, Ocelot Bio, and Cymabay therapeutics. None of the aforementioned disclosures are related to the study. Remaining authors have no disclosures to report."

Evidence found in paper:

"FUNDING INFORMATION ASA, GC, APD are funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health; ASA K23 DK128567, GC K23 DK131278, and APD K23 DK123408. This work is independent of their funding."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025